Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer

Brodie, 1987, Aromatase inhibitors: basic and clinical studies, J. Steroid Biochem., 27, 899, 10.1016/0022-4731(87)90166-X Brodie, 1986, Aromatase inhibitors and their potential clinical significance, J. Steroid Biochem., 25, 859, 10.1016/0022-4731(86)90317-1 Uzgris, 1977, Sterioselective inhibition of cholesterol side chain cleavage by enantiomers of aminoglutethimide, Endocrinology, 101, 89, 10.1210/endo-101-1-89 Dowsett, 1985, Low dose aminoglutethimide and aromatase inhibition, Lancet, 1, 175, 10.1016/S0140-6736(85)91955-5 Miller, 1989, Aromatase inhibitors in the treatment of advanced breast cancer, Cancer Treat. Rev., 16, 83, 10.1016/0305-7372(89)90012-1 Stein, 1990, Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione, Cancer Chemother. Pharmac., 26, 75, 10.1007/BF02940300 Dowsett, 1990, Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients, Clin. Endocr., 32, 623, 10.1111/j.1365-2265.1990.tb00906.x Steele, 1987, In-vitro and in-vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A, Steroids, 50, 147, 10.1016/0039-128X(83)90068-5 Lipton, 1990, A phase I trial of CGS 16949A. A new aromatase inhibitor, Cancer, 65, 1279, 10.1002/1097-0142(19900315)65:6<1279::AID-CNCR2820650604>3.0.CO;2-3 Harvey, 1990, Clinical trials with the aromatase inhibitor CGS 16949A in advanced breast cancer: the U.S. experience Lipton, 1987, Aromatase activity in primary and metastatic human breast cancer, Cancer, 59, 779, 10.1002/1097-0142(19870215)59:4<779::AID-CNCR2820590419>3.0.CO;2-U Raats, 1992, A study of fadrozole (CGS 16 949A), a new aromatase inhibitor, in post menopausal women with advanced metastatic breast cancer, J. Clin. Oncol., 10, 111, 10.1200/JCO.1992.10.1.111 Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am. J. Clin. Oncol. (CCT), 5, 649, 10.1097/00000421-198212000-00014 Fisher, 1934 Gelber, 1985, Planning and reporting of clinical trials, 406 Santen, 1986, Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives, Breast Cancer Res. Treat., 7, 23 Longcope, 1978, Aromatization of androgens by muscle and adipose tissue in vivo, J. Clin. Endocr. Metab., 46, 146, 10.1210/jcem-46-1-146 Longcope, 1982, Methods and results of aromatization studies in vivo, Cancer Res., 42, 3307 Brodie, 1986, Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors, Crit. Rev. Oncol. Hemat., 5, 361, 10.1016/S1040-8428(86)80003-8 Powles, 1983, The role of aromatase inhibitors in breast cancer, Sem. Oncol., 10, 20 Harris, 1985, Could aminoglutethimide replace adrenalectomy?, Breast Cancer Res. Treat., 5, 201, 10.1007/BF01806770 Stuart-Harris, 1984, Aminoglutethimide in the treatment of advanced breast cancer, Cancer Treat. Rev., 11, 189, 10.1016/0305-7372(84)90008-2 Cunningham, 1987, Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer, Cancer Chemother. Pharmac., 20, 253, 10.1007/BF00570496 Falkson, 1983, A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer, Cancer Chemother. Pharmac., 11, 16, 10.1007/BF00257409